Overview of clinical studies with sodium selenite1998 – 2011
Note: Even if not mentioned specifically, sodium selenite has always been given in addition to standard therapy, not as an alternative to standard therapy!
Note: Cancer prevention studies are not included. Some minor pilot studies or preliminary publications have also been omitted, if consecutive high quality studies have been published in the meantime.
Design/application Supplierof sodium selenite
Different increases in Burk et al., Cancer
as selenite, Se yeast and Se-methionine66 healthy volunteers ?
Increase of serum Se Broome et al., Am. J.
immune response, T-helper cells Better resistance to polio virus challenge
15 sodium selenite (50 mcg / d for 28 days)
cal improvement (CD4 = T-helper cells!), no difference in viral load
intracranial pressure Elem. Res. 62: 1 – 6 and other symptoms
10 of 12 pts. showed Micke et al., Int. J.
marked reduction of Radiation Oncol. Biol.
control), single high – 9 (2000); Kasserol-
inflammation, no use 18: 2227 – 30 (1998)
effects (20,5 % heavy diarrhea grade 2 vs. 44,5 %), no reduction of therapy efficiency (trend toward longer survival)
levels of blood Se and GPx activity, in Se group back to normal values
reduction of therapy Anticancer Res. 30:
significant reduction Princ. Pract. 13: 185
significant improve-ment of quality of life, tracheostomy avoided in 65 % of pts. with endolaryn-geal edema
ced immune respon- cher et al., Biol. Trace
higher T-cell activity 111 (2000)against tumor cells vs. 7.1 % in placebo group)
in apoptotic lympho- Trace Elem. Res. 127:
Chemicals, St. Louis, ma cells (78,9 vs. 58,9 200 – 210 (2009);
%), higher efficacy of Asfour et al., Biol.
et al., Biol. Trace Elem. Res. 110: 19 – 32 (2006)
Cassel Laboratoires, antioxidant status in Chim. Acta 373: 92 –
27 pts. RT36 pts. RT + 400 mcg Se p.o. /d for 6 mo.
Significant reduction Zimmermann et al.,
phlebitis > grade 2 + 1000 mcg Se i.v. in 500 ml saline immediately before n
100 pts. with elective selenase®, biosyn,
128 pts. 500 mcg Se p.o. 132 pts. 200 mcg Se p.o. 132 pts. placebo 12 weeks
blood Se concentrati- Med. Klin. 94: S3, 78
No reduction of TPO Bonfig et al., Scienti-
antibodies, reduction fic World Journal 10:
Better quality of life, Karanikas et al.,
TPO antibodies, more Ernährung & Medizin
Significant reduction Gärtner and Gasnier,
in groups with further Biofactors 19: 165 –
Significant reduction Gärtner et al., J. Clin.
of TPO Ab (63,6 % vs. Endocrinol. Metab.
group with complete-ly normalized antibody conc. (vs. 2 pts.) and normal echogenicity of thyroid
ment of quality of life, 1920 – 1931 (2011)
B IFN + antioxidant cocktail incl. 400 mcg Se p.o. C IFN + antioxidant cocktail + vit. E
Plasma Se level and Berger et al., Crit.
Pts. with > 4 days of Andrews et al., BMJ
Pancreatitis, acute 67 pts. 32 pts. 2000
No effect on clinical Lindner et al., Med.
– 5, then 300 until release from ICU35 pts. placebo
No effect on clinical Wollschläger et al.,
outcome (prevention Med. Klin. 94: S3, 81
- non-fortified (35 mcg/d)- selenite (134 mcg/d)- selenate (140 mcg/d)
errors in publication 37: 808 – 815 (2011)
SELENIO®, Laborato- Significant decrease Manzanares et al.,
pneumonia after hospital discharge, no adverse events.
10 pts. high dose Se ries Rivero, Buenos
endpoints, very high Nutrition 26: 634 –
No clinical benefit, no Forceville, J. Trace
Per-protocol-analysis: Angstwurm et al.,
reduction of mortality Crit. Care Med. 35:
ml, one as bolus injection within 30 min, rest as cont. i.v. with 2 ml/h), 1000 mcg Se cont. i.v. on day 2 – 14 97 pts. without Se
No change in thyroid Angstwurm et a., Eur.
21 pts. placebo (= 35 mcg Se in TPN solution)
Thank you for choosing our Teen Winter Caravan. This Parent/Camper Info packet should answer many of your questions. If you have any additional questions, please contact Jessie Bringelson at 805-480-0309 or [email protected]. W INTER CARAVAN January 2 – 5 Teens entering 9-12 grade CAMPER/PARENT RALLY NIGHT (Mandatory for each camper and one parent or guardian) Get informati